Agomab Therapeutics (AGMB) Enterprise Value (2024 - 2025)
Agomab Therapeutics (AGMB) posted quarterly Enterprise Value of -$135.6 million for Q4 2025, up 25.98% year-over-year from -$107.7 million in Q4 2024, and up 25.98% quarter-over-quarter from -$183.2 million in Q4 2024.
Agomab Therapeutics (AGMB) Enterprise Value (2024 - 2025) Analysis & Trends
Agomab Therapeutics' Enterprise Value history runs 2 years deep, the most recent figure standing at -$135.6 million for Q4 2025.
- In Q4 2025, Enterprise Value rose 25.98% year-over-year to -$135.6 million; the TTM figure through Dec 2025 stood at -$135.6 million (up 25.98% YoY), while the FY2025 annual figure was -$135.6 million, up 26.92% from the prior year.
- Enterprise Value for Q4 2025 stood at -$135.6 million, up from -$183.2 million in the prior quarter.
- The five-year high for Enterprise Value was -$135.6 million in Q4 2025, with the low at -$183.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 2.12 Bn |
| 10 | Agomab Therapeutics | 7.20 Mn | -250.38 Mn | - | -257.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -135.63 Mn |
| Dec 31, 2024 | -183.22 Mn |